Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4336780 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1GAACTSLNPC1 | |
| SCHEMBL4336889 | 0.83 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1GAACTSLMAPT | |
| SCHEMBL4336892 | 0.83 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1GAACTSLMAPT | |
| SCHEMBL4330786 | 0.80 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1CTSLNPC1RAB9A | |
| SCHEMBL4330782 | 0.80 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1CTSLNPC1RAB9A | |
| SCHEMBL4325317 | 0.75 | MAPT (0.76) | SMN1; SMN2ALDH1A1GAACTSLNPC1 | |
| SCHEMBL4325315 | 0.75 | MAPT (0.76) | SMN1; SMN2ALDH1A1GAACTSLNPC1 | |
| SCHEMBL31758603 | 0.73 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1GAACTSLNPC1 | |
| SCHEMBL7132970 | 0.72 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL5615197 | 0.71 | KDM4E (0.81) | ALDH1A1GAARAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | SMN1; SMN2 4740/4885ALDH1A1 1459/4885GAA 2113/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | SMN1; SMN2 4815/4885ALDH1A1 1173/4885GAA 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.